✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Fluzoparib is an investigational drug.
There have been 39 clinical trials for Fluzoparib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 19th 2020.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Lung Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Tianjin Medical University Second Hospital, and Tianjin Medical University Cancer Institute and Hospital.
There are two US patents protecting this investigational drug and twenty-one international patents.
Recent Clinical Trials for Fluzoparib
|Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment||Xiaohua Wu MD||Phase 2|
|A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers||Suzhou Suncadia Biopharmaceuticals Co., Ltd.||Phase 2|
|A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer||The Second Affiliated Hospital of Shandong First Medical University||Phase 2|
Top disease conditions for Fluzoparib
Top clinical trial sponsors for Fluzoparib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fluzoparib||See Plans and Pricing||Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof||Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)||See Plans and Pricing|
|Fluzoparib||See Plans and Pricing||Methods of using phthalazinone ketone derivatives||Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Fluzoparib||Australia||AU2011288876||2030-08-09||See Plans and Pricing|
|Fluzoparib||Brazil||BR112013002220||2030-08-09||See Plans and Pricing|
|Fluzoparib||Canada||CA2806324||2030-08-09||See Plans and Pricing|
|Fluzoparib||China||CN102372716||2030-08-09||See Plans and Pricing|
|Fluzoparib||China||CN102686591||2030-08-09||See Plans and Pricing|
|Fluzoparib||European Patent Office||EP2604610||2030-08-09||See Plans and Pricing|
|Fluzoparib||Spain||ES2582315||2030-08-09||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|